Lotte Biologic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

South Korea CDMO Lotte Biologics and Merck KGaA signed a partnership deal focused on expanding biopharmaceutical production and process development.

Lotte Biologics, a South Korean contract development and manufacturing organization, and Merck’s process solutions arm signed a letter of intent for a strategic partnership in biopharmaceutical manufacturing and process development, the company said Friday. Under the partnership, Lotte Biologics plans to purchase raw materials and solutions from Merck for its development and production of pharmaceutical product...

SAN FRANCISCO -- Lotte Biologics will begin production of its antibody-drug conjugates at its US plant by the first quarter of 2025, according to its CEO Richard Lee, who spoke at a meeting with reporters on Monday, held on the sidelines of the J.P. Morgan Healthcare Conference. As ADCs have emerged as a promising class of treatments, the Korean contract drug manufacturer has received a myriad of requests from potent...

Shin Yoo-yeol, the heir apparent of Lotte Group's owner family, will be in charge of finding the firm’s next growth engines and mapping out its medium- to long-term vision, the company said Wednesday during a year-end reshuffle of top management.

BARCELONA, Spain -- Lotte Biologics will begin antibody-drug conjugate manufacturing at its site near Syracuse, New York, starting in the first quarter of 2025, according to CEO Lee Won-jik, who also goes by Richard Lee. The company expects its ADC production to account for some 10 percent of its total sales in 10 years, Lee added. “Lotte Biologics is building an ADC facility within its Syracuse facilities. The...